Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies.

[1]  E. López-Granados,et al.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. , 2010, The Journal of allergy and clinical immunology.

[2]  D. Mannino,et al.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.

[3]  S. Sonnappa,et al.  Bronchiectasis secondary to primary immunodeficiency in children: Longitudinal changes in structure and function , 2009, Pediatric pulmonology.

[4]  A. Fischer,et al.  The European internet‐based patient and research database for primary immunodeficiencies: results 2006–2008 , 2009, Clinical and experimental immunology.

[5]  D. Hansell,et al.  Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.

[6]  J. Orange,et al.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.

[7]  S Senn,et al.  Repeated measures in clinical trials: simple strategies for analysis using summary measures. , 2000, Statistics in medicine.

[8]  D. Postma,et al.  Decline of FEV1 by age and smoking status: facts, figures, and fallacies. , 1997, Thorax.

[9]  G. Borsboom,et al.  Discrepancies between longitudinal and cross-sectional change in ventilatory function in 12 years of follow-up. , 1994, American journal of respiratory and critical care medicine.

[10]  M. Lebowitz,et al.  Changes in the normal maximal expiratory flow-volume curve with growth and aging. , 1983, The American review of respiratory disease.